Advertisement

Aminoglycoside Nephrotoxicity: Mechanism and Prevention

  • Marc E. De Broe
  • Rubén A. Giuliano
  • Gert A. Verpooten
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 252)

Abstract

Nephrotoxicity limits the clinical utility of aminoglycosides (Lietman, 1985). Therefore, the identification of factors associated with a greater incidence of renal damage is critical. These factors can be classified in those related to the drug and its administration and those related to the clinical condition of the patient (Table 1).

Keywords

Proximal Tubular Cell Renal Uptake Renal Handling Cortical Uptake Aminoglycoside Nephrotoxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Blaser, J., Stone, B.B. and Zinner, S.H. 1985. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment model. Antimicrob. Agents Chemother. 27: 343–349.PubMedCrossRefGoogle Scholar
  2. Collier, V.V., Lietman, P.S. and Mitch, W.E. 1979. Evidence of luminal uptake of gentamicin in the perfused rat kidney. J. Pharmacol. Exp. Ther. 210: 247–251.PubMedGoogle Scholar
  3. Craig, W.A. and Vogelman, B. 1987. The postantibiotic effect. Ann. Intern. Med. 106: 900–902.PubMedGoogle Scholar
  4. De Broe, M.E., Paulus, G.J., Verpooten, G.A., Giuliano, R.A., Roels, F. and Tulkens, P.M. 1983. In “Proceedings of the 13th. International Congress of Chemotherapy: Side effects of antibiotics”. August 28-September 2, 1983, SE 8.4/1, part 86. Spitzy, K.H. and Karrer, K, eds., 86/11–86/23.Google Scholar
  5. De Broe, M.E., Paulus, G.J., Verpooten, G.A., Roels, F., Buyssens, N., Wedeen, R.P. 1984. Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Int. 25: 643–652.PubMedCrossRefGoogle Scholar
  6. De Broe, M.E. 1985. Prevention of aminoglycoside nephrotoxicity. In: Proceedings of the European Dialysis and Transplantation Association- European Renal Association. Davison, A.M., and Guillow, P.J., eds., Bailliere Tindall Pub., London, Vol 22: 959–973.Google Scholar
  7. Fabre, J., Rudhart, M., Blanchard, P. and Regamey, C. 1976. Persistence of sisomicin and gentamicin in renal cortex and medulla compared with other organs and serum of rats. Kidney Int. 10: 444–449.PubMedCrossRefGoogle Scholar
  8. Giuliano, R.A., Paulus, G.J., Verpooten, G.A., Pattyn, V.M., Pollet, D.E., Nouwen, E.J., Laurent, G., Carlier, M.B., Maldague, P., Tulkens, P.M. and De Broe, M.E. 1904. Recovery of cortical phospholipidosis and necrosis after acute gentamicin loading in rats. Kidney Int 26: 838–847.CrossRefGoogle Scholar
  9. Giuliano, R.A., Verpooten, G.A., Verbist, L., Wedeen, R.P. and De Broe M.E. 1986 a. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J. Pharmacol. Exp. Ther. 236: 1470–475.Google Scholar
  10. Giuliano, R.A., Verpooten, G.A. and De Broe, M.E. 1986 b. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides. Am. J. Kidney Dis. 8: 297–303.PubMedGoogle Scholar
  11. Houghton, D.C., Hartnett, M.L., Campbell-Boswell, M., Porter, G. and Bennett, W. 1976. A light and electron microscopic analysis of gentamicin nephrotoxicity in rats. Am. J. Pathol. 82: 589–612.PubMedGoogle Scholar
  12. Josepovitz, C., Pastoriza-Munoz, E., Timmerman, D., Scott, M., Feldman, S. and Kaloyanides, G.J. 1982. Inhibition of gentamicin uptake in rat renal cortex in vivo by aminoglycosides and organic polycations. J. Pharm. Exp. Ther. 233: 314–321.Google Scholar
  13. Just, M. and Habermann, E. 1977. The renal handling of polybasic drugs. 2. In vitro studies with brush border and lysosomal preparations. Naunyn-Schmiedeberg’s Arch. Pharmacol. 300: 67–76.Google Scholar
  14. Kaloyanides, G.J. and Pastoriza-Munoz, E. 1980. Aminoglycoside nephrotoxicity. Kidney Int. 18: 571–582.PubMedCrossRefGoogle Scholar
  15. Kleinknecht, D., Landais, P. and Goldfard, B. 1985 Drug-associated acute renal failure. A prospective multicenter report. In: Proceedings of the European Dialysis and Transplantation Association – European Renal Association. Davison, A.M. and Guillou, P.J. eds. Bailliere Tindall Pub. London 22: 1002–1007.Google Scholar
  16. Kosek, J.C., Mazz, R.I. and Cousins, M.J. 1974. Nephrotoxicity of gentamicin. Lab. Invest. 30: 48–57.PubMedGoogle Scholar
  17. Laurent, G., Carlier, M.B., Rollman, B., Van Hoof, F. and Tulkens, P.M. 1982. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem. Pharmacol. 31: 3861–387O.PubMedCrossRefGoogle Scholar
  18. Lietman, P.S. 1985. Aminoglycosides and spectinomycin: aminocyclitols. In: Principles and practice of infectious diseases. 2nd Edition. Part I: Basic principles in the diagnosis and management of infectious diseases. Mandel, G.L., Douglas Jr, R.G. and Bennett, J.E., eds. John Wiley and Sons, New York, Chichester: 192–206.Google Scholar
  19. Moore, R.D., Smith, C.R., Lipsky, J.J., Mellitis E.D., and Lietman, P.S. 1981. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann. Intern. Med. 100: 352–357.Google Scholar
  20. Pattyn, V.M., Verpooten, G.A., Giuliano, R.A., Zheng, F.L. and De Broe, M.D. 1987. Effect of hyperfiltration, proteinuria and diabetes mellitus on the uptake kinetics of gentamicin in the kidney cortex of rats. J. Pharmacol. Exp. Ther. 244: 694–698.Google Scholar
  21. Powel, S.H., Thompson, W.L., Luthe, M.A., Stern, R.C., Grossniklaus, D.A., Bloxham, D.D., Groden, D.L., Jacobs, M.R., Discenna, A.O., Cash, H.A. and Klinger, J.D. 1983. Once daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin and tobramycin. J. Infect. Dis. 147: 918–932.CrossRefGoogle Scholar
  22. Reiner, N.E., Bloxham, D.D., and Thompson, W.L. 1978. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J. Antimicrob. Chemother. 4 (Suppl.A): 85–101.PubMedCrossRefGoogle Scholar
  23. Reymann, M.T., Bradac, J.A. and Cobbs, C.G. 1979. Correlation of aminoglycoside dosages with serum concentrations during therapy of serious gram negative bacillary disease. Antimicrob. Agents Chemother. l6: 353–365.CrossRefGoogle Scholar
  24. Silverblatt, F. and Kuehn, C. 1979. Autoradiography of gentamicin uptake by the rat proximal tubular cell. Kidney Int. 15: 335–3-5.PubMedCrossRefGoogle Scholar
  25. Smith, C.R., Maxwell, R.R. and Edwards, C.Q. 1978. Nephrotoxicity induced by gentamicin and amikacin. John Hopkins Med. J. 142: 85–90.Google Scholar
  26. Tulkens, P.M., De Broe, M.E., Maldague, P. and Heuson-Stiennon, J.A. 1984. Lysosomal alterations in aminoglycoside-induced acute renal failure. In: Acute Renal Failure: correlations between morphology and function. Solez, K., and Whelton, A., eds. Marcel Dekker, Pub., New York: 299–327.Google Scholar
  27. Verpooten, G.A., Giuliano, R.A., Pattyn, V.M., Schärpé, S.L. and De Broe, M.E. 1986. Renal cortical uptake kinetics of gentamicin in rats with impaired renal fimction. Am. J. Kidney Dis. 8: 304–307.PubMedGoogle Scholar
  28. Verpooten, G.A., Giuliano, R.A., Verbist, L., Eestermans, G. and De Broe, M.E. 1988. A once-daily dosage schedule decreases the acciomulation of gentamicin and netilmicin in the renal cortex of humans. Submitted.Google Scholar
  29. Wedeen, R.P., Batuman, V., Cheeks, E.M., Marquet, E. and Sobel, H. 1983.Transport of gentamicin in rat proximal tubule. Lab. Invest. 48:212–223.PubMedGoogle Scholar
  30. Whelton, A. 1985 Therapeutic initiative for avoidance of aminoglycoside toxicity. J. Clin. Pharmacol. 25: 67–81.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Marc E. De Broe
    • 1
  • Rubén A. Giuliano
    • 1
  • Gert A. Verpooten
    • 1
  1. 1.Department of Nephrology-HypertensionUniversity Hospital AntwerpenAntwerpenBelgium

Personalised recommendations